secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001682852-23-000025
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q2 net loss $1.4B, EPS -$3.62; revenue $344M (-93% YoY); FY23 sales guidance $6-8B
--------------------------------------------------------------------------------

- Q2 revenue $344M vs $4.7B YoY; product sales $293M, down 94% due to lower COVID vaccine volume.
- Net loss $1.4B vs net income $2.2B YoY; diluted EPS -$3.62 vs +$5.24.
- Cost of sales $731M includes $464M inventory write-downs, $135M unutilized capacity, $75M purchase commitment losses.
- Guides FY23 COVID vaccine sales $6-8B; expects ~$1B of APAs deferred to 2024; cost of sales now $3.5-4B.
- RSV vaccine submitted globally for approval; Phase 3 melanoma combo trial with Merck initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/0001682852-23-000025-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285223000025/mrna-20230803.htm
  HTML page:      https://secwatch.observer/filing/0001682852-23-000025

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer